Form 4: Capricor Therapeutics Director Frank Litvack Acquires Shares and Warrants

Director Frank Litvack acquired 20,391 shares and warrants of Capricor Therapeutics, increasing his indirect holdings.

Summary

• Frank Litvack, a director at Capricor Therapeutics, acquired 20,391 shares of common stock at a price of $1.1 per share.
• These shares were acquired indirectly through the Litvack Curtis Family Trust, for which Mr. Litvack serves as trustee.
• Mr. Litvack also acquired 20,391 warrants, also indirectly through the family trust, with an exercise price of $1.1.
• The warrants have an expiration date of December 17, 2024.
• Following these transactions, Mr. Litvack's indirect holdings include 46,278 shares and 20,391 warrants held by the family trust.

Sentiment

Score: 6

Explanation: The document is neutral, detailing a routine insider transaction. It doesn't indicate any significant positive or negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders when they trade company securities. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transactions are typical for directors who may receive stock or options as part of their compensation or investment strategy.
• The acquisition of shares and warrants at a set price is a common practice and does not indicate any unusual activity compared to other companies.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates

Keywords

Capricor Therapeutics, Frank Litvack, insider trading, Form 4, stock acquisition, warrants, director, family trust